tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Alnylam Pharmaceuticals Inc

ALNY
Add to Watchlist
204.830USD
-81.790-28.54%
Market hours （ET）Quotes delayed by 15 min
27.11BMarket Cap
50.13P/E TTM

Alnylam Pharmaceuticals Inc

204.830
-81.790-28.54%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

ALNY Financials

See Alnylam Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Alnylam Pharmaceuticals Inc Earnings Date

Latest Release
Jul 30, 2026
EPS / Forecast
--/1.55
Revenue / Forecast
--/1.32B
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
3.71B
65.19%
EPS(YoY)
2.39
209.91%
Analyst Rating
BUY
2026/07/30
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
342.66%1.23
449.70%1.55
317.31%1.41
320.15%1.91
-280.74%-0.51
15.20%-0.44
40.89%-0.65
-173.53%-0.87
93.98%-0.13
62.74%-0.52
34.79%-1.10
--1.18
---2.21
---1.40
---1.68
---7.62
----
----
----
----
Revenue
51.50%1.17B
96.43%1.17B
84.95%1.10B
149.35%1.25B
17.26%773.69M
20.20%594.19M
34.90%593.17M
-33.26%500.92M
107.00%659.83M
54.82%494.33M
31.25%439.72M
183.96%750.53M
41.78%318.75M
49.72%319.29M
29.59%335.04M
40.86%264.31M
1.93%224.82M
20.10%213.26M
58.07%258.54M
49.09%187.63M
Net Profit
348.19%164.49M
458.38%205.99M
322.56%186.42M
325.05%251.08M
-292.43%-66.28M
12.82%-57.48M
39.24%-83.76M
-175.51%-111.57M
93.88%-16.89M
62.13%-65.94M
33.55%-137.87M
136.40%147.75M
0.50%-276.02M
27.56%-174.10M
19.72%-207.49M
-98.48%-405.92M
-46.34%-277.40M
-20.00%-240.34M
-6.13%-258.46M
19.26%-204.51M
Net Margin
263.83%14.03%
282.44%17.65%
220.34%16.99%
190.25%20.10%
-234.67%-8.57%
27.47%-9.67%
54.96%-14.12%
-213.14%-22.27%
97.04%-2.56%
75.54%-13.34%
49.37%-31.35%
--19.69%
---86.59%
---54.53%
---61.93%
---131.50%
----
----
----
----
Gross Margin
-8.57%74.54%
-6.97%81.91%
-8.55%75.60%
1.36%83.98%
-9.01%81.52%
1.60%88.04%
2.72%82.67%
-6.66%82.85%
22.36%89.59%
4.63%86.65%
-4.99%80.47%
--88.77%
--73.22%
--82.82%
--84.70%
--83.26%
----
----
----
----
Debt to assets ratio
118.54%49.13%
116.79%52.76%
124.82%54.33%
112.11%51.63%
-11.86%22.48%
-8.90%24.34%
-9.33%24.17%
-8.36%24.34%
-14.82%25.51%
-10.97%26.72%
-7.05%26.65%
--26.56%
--29.94%
--30.01%
--28.68%
--28.74%
----
----
----
----
Income Statement
Revenue
51.50%1.17B
96.43%1.17B
84.95%1.10B
149.35%1.25B
17.26%773.69M
20.20%594.19M
34.90%593.17M
-33.26%500.92M
107.00%659.83M
54.82%494.33M
31.25%439.72M
183.96%750.53M
41.78%318.75M
49.72%319.29M
29.59%335.04M
40.86%264.31M
1.93%224.82M
20.10%213.26M
58.07%258.54M
49.09%187.63M
Operating profit
795.12%112.60M
1386.07%268.64M
225.26%131.72M
578.49%367.98M
-133.32%-16.20M
141.62%18.08M
9.66%-105.16M
-135.96%-76.91M
121.15%48.61M
71.01%-43.44M
38.28%-116.40M
182.88%213.87M
-19.90%-229.83M
-2.10%-149.81M
3.06%-188.61M
-42.03%-258.04M
-31.15%-191.69M
21.22%-146.73M
-0.17%-194.56M
19.33%-181.68M
Net Profit
348.19%164.49M
458.38%205.99M
322.56%186.42M
325.05%251.08M
-292.43%-66.28M
12.82%-57.48M
39.24%-83.76M
-175.51%-111.57M
93.88%-16.89M
62.13%-65.94M
33.55%-137.87M
136.40%147.75M
0.50%-276.02M
27.56%-174.10M
19.72%-207.49M
-98.48%-405.92M
-46.34%-277.40M
-20.00%-240.34M
-6.13%-258.46M
19.26%-204.51M
Balance Sheet
Current assets
26.80%4.62B
29.10%4.22B
22.92%4.05B
17.80%3.95B
14.84%3.64B
9.36%3.27B
10.48%3.30B
12.39%3.36B
25.71%3.17B
17.61%2.99B
10.79%2.98B
10.95%2.99B
2.12%2.52B
-1.88%2.54B
-4.14%2.69B
0.58%2.69B
-9.30%2.47B
4.84%2.59B
7.41%2.81B
4.72%2.68B
Total current liabilities
16.27%1.51B
25.46%1.35B
23.61%1.47B
27.43%1.56B
23.27%1.30B
14.22%1.08B
22.58%1.19B
28.52%1.22B
33.81%1.06B
39.85%941.71M
26.03%967.79M
22.90%949.78M
19.91%788.64M
11.13%673.39M
10.38%767.91M
26.55%772.79M
18.58%657.68M
22.46%605.96M
18.87%695.71M
27.16%610.66M
Total assets
21.74%5.56B
21.73%5.13B
17.13%4.97B
15.38%4.85B
13.88%4.57B
10.18%4.21B
10.71%4.24B
9.53%4.21B
17.85%4.01B
12.75%3.82B
7.99%3.83B
8.59%3.84B
2.16%3.40B
-1.21%3.39B
-2.66%3.55B
1.81%3.54B
-5.10%3.33B
5.48%3.43B
6.93%3.64B
4.99%3.47B
Total liabilities
-2.57%4.20B
-1.08%4.05B
0.10%4.18B
10.67%4.62B
7.54%4.32B
1.35%4.10B
3.02%4.17B
4.19%4.17B
5.31%4.01B
10.75%4.04B
9.34%4.05B
11.16%4.00B
20.80%3.81B
20.41%3.65B
21.26%3.70B
32.63%3.60B
18.76%3.15B
30.20%3.03B
27.78%3.06B
29.83%2.72B
Total equity
440.37%1.35B
831.59%1.08B
1076.33%789.18M
622.92%233.89M
8270.56%250.59M
152.64%115.44M
130.41%67.09M
119.51%32.35M
99.25%-3.07M
15.42%-219.27M
-39.45%-220.64M
-145.23%-165.87M
-331.84%-408.13M
-164.62%-259.24M
-126.90%-158.22M
-108.95%-67.64M
-79.37%176.04M
-56.69%401.17M
-42.12%588.20M
-37.79%755.89M
Cash Flow Statement
Net operating income
112.53%326.72M
159.59%70.50M
272.78%163.56M
643.84%325.11M
23.82%153.73M
-45.14%-118.31M
-217.71%-94.66M
-87.84%43.71M
310.49%124.16M
51.03%-81.52M
77.42%-29.80M
411.76%359.41M
51.97%-58.99M
2.76%-166.47M
12.10%-131.98M
13.99%-115.28M
-0.79%-122.82M
27.36%-171.19M
-21.92%-150.14M
-21.49%-134.04M
Net investment
-157.08%-363.46M
-122.45%-25.54M
29.76%-37.17M
1756.55%501.11M
-516.56%-141.38M
268.25%113.77M
78.01%-52.91M
-181.03%-30.25M
489.53%33.94M
11.28%-67.62M
-72.01%-240.66M
-103.43%-10.76M
-106.10%-8.71M
48.30%-76.22M
66.16%-139.91M
455.60%313.89M
-9.06%142.79M
-306.61%-147.42M
-322.32%-413.40M
-775.01%-88.27M
Net financing
-32.59%36.24M
-64.35%15.71M
46.20%45.32M
-536.33%-448.35M
-59.12%53.76M
52.48%44.08M
-20.98%31.00M
210.08%102.75M
146.27%131.50M
-37.65%28.91M
-38.16%39.23M
-88.84%33.14M
76.00%53.39M
32.66%46.37M
-78.30%63.44M
-48.24%297.02M
-90.80%30.34M
-31.70%34.96M
34.11%292.29M
1580.50%573.84M

FAQs

What is the total revenue of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 3.71B, with a year-on-year change of 2.25B.

What are the current assets of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its current assets were 4.05B, with a year-on-year change of 22.92.

What are the total assets of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its total assets of Alnylam Pharmaceuticals Inc were 4.97B, with a year-on-year change of 17.13.

What are the total liabilities of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Alnylam Pharmaceuticals Inc were 4.18B, with a year-on-year change of 0.10.

What is the total equity of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its total equity of Alnylam Pharmaceuticals Inc was 789.18M, with a year-on-year change of 1076.33.

What is the net operating income of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Alnylam Pharmaceuticals Inc was 501.58M, with a year-on-year change of 383.56.

What is the net investment of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its net investment of Alnylam Pharmaceuticals Inc was 436.33M, with a year-on-year change of 473.44.

What is the net financing of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its net financing of Alnylam Pharmaceuticals Inc was -305.19M, with a year-on-year change of -203.75.

What is the Earnings Per Share (EPS) of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was 2.39, with a year-on-year change of 209.91.

What is the net income of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its net income was 313.75M, with a year-on-year change of 212.79.

What is the net margin of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was 8.45, with a year-on-year change of 168.28.

What is the gross margin of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 81.64, with a year-on-year change of -4.64.

What is the debt-to-asset ratio of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 54.33, with a year-on-year change of -6.81.

What is the Return on Assets (ROA) of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was 6.82, with a year-on-year change of 198.87.

What is the operating profit of Alnylam Pharmaceuticals Inc?

According to Alnylam Pharmaceuticals Inc's FY2025 earnings report, its operating profit was 501.58M, with a year-on-year change of 383.56.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy